Indication name: Alport
Syndrome
Alport Syndrome – Market outlook, Epidemiology, Market Forecast and
Competitive Landscape Report – 2019 To 2030
Alport syndrome is a genetic
condition characterized by kidney disease, hearing loss, and eye abnormalities.
Alport syndrome is caused by mutations in three possible genes: COL4A3, COL4A4,
or COL4A5. These genes each provide instructions for making one component of a
protein called type IV collagen, which plays an important role in the glomeruli
of the kidneys.
Thelansis Epidemiology
research study indicates Alport syndrome is estimated to affect
approximately 1 in 5,000-10,000 people in the general population in the United
States, which means that approximately 30,000-60,000 people in the United
States have the disorder. Alport syndrome is estimated to account for 3% of
children with chronic kidney disease and 0.2% of adults with end-stage renal
disease in the United States.
Competitive landscape of Alport
syndrome includes country specific approved as well as pipeline therapies. Any
asset/ product specific designation or review and Accelerated Approval are
being tracked and supplemented with analyst commentary.
KOLs insights of Alport syndrome
across 8 MM market from center of Excellence/ Public/ Private hospitals
participated in the study. Insights around current treatment landscape,
epidemiology, clinical characteristics, future treatment paradigm and Unmet
needs.
Alport syndrome Market Forecast:
Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data
Inputs with sourcing, Market Event and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden and pricing scenario, Summary and Insights.
No comments:
Post a Comment